HROW (Harrow) Loans Receivable: $0.0 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HROW Harrow Inc HROW
80 GF Score
Price $41.63
GF Value $42.00
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Harrow Loans Receivable?

Harrow HROW +5.36% 80 Loans Receivable is $0.0 Mil as of Jun. 2026. GuruFocus rates HROW with a GF Score™ of 80/100 and a GF Value™ of $42.00 (Fairly Valued). The stock has 4 warning signs investors should review.

Harrow's Loans Receivable for the quarter that ended in Jun. 2026 was $0.0 Mil.

Harrow Loans Receivable Historical Data

* Premium members only.

The historical data trend for Harrow's Loans Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Harrow Loans Receivable Chart

Harrow Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Loans Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Harrow Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Loans Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
HROW
80GF Score
Harrow Inc HROW
Loans Receivable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Harrow Loans Receivable Calculation

Loans Receivable are the funds that a company has lent but have not yet been repaid.

Frequently Asked Questions Learn more about Loans Receivable →
What does a Loans Receivable of $0.0 Mil mean?
Harrow (HROW) has a Loans Receivable of $0.0 Mil as of Jun. 2026. Loans Receivable are the funds that a company has lent but have not yet been repaid. View historical data on Harrow and its competitors.
Is Harrow's Loans Receivable too high?
Harrow's current Loans Receivable is $0.0 Mil. Overall, Harrow has a GF Score™ of 80/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Harrow's Loans Receivable compare to XERS and PRGO?
Harrow's Loans Receivable of $0.0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Loans Receivable for a Drug Manufacturers company?
A good Loans Receivable depends on the Drug Manufacturers industry context. However, Loans Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Loans Receivable mean?
A high Loans Receivable can signal that a stock is expensive relative to its fundamentals. Loans Receivable are the funds that a company has lent but have not yet been repaid. View historical data on Harrow and its competitors. Harrow's current Loans Receivable is $0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Harrow stock overvalued right now?
Based on GuruFocus' analysis, Harrow (HROW) is currently considered Fairly Valued. The stock's GF Value™ is $42.00, compared to a current price of $41.63 — trading 0.9% below its estimated fair value. The current Loans Receivable is $0.0 Mil. Harrow's overall GF Score™ is 80/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Loans Receivable calculated?
Loans Receivable is calculated from a company's financial statements. For Harrow (HROW), the current Loans Receivable is $0.0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Harrow (HROW) Overvalued in 2026?

Based on GuruFocus' analysis, Harrow stock appears to be undervalued. The current stock price of $41.63 is trading 0.9% below its estimated GF Value™ of $42.00. GuruFocus considers Harrow to be Fairly Valued.

Key valuation signals for HROW:

  • Loans Receivable: $0.0 Mil
  • GF Value™: $42.00 vs. price of $41.63 (0.9% below fair value)
  • GF Score™: 80/100 with 4 warning signs

No single metric tells the full story. See the HROW stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Harrow Business Description

Other Exchanges 3IP:Germany
Address 1A Burton Hills Boulevard, Suite 200, Nashville, TN, USA, 37215
Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company partners with U.S. eyecare professionals to develop products used to manage ophthalmic conditions affecting both the front and back of the eye, such as dry eye disease, cataracts, refractive errors, glaucoma, etc. Its portfolio of branded ophthalmic pharmaceuticals includes Iheezo, Vevye, Byooviz Opuviz, Natacyn, Maxitrol, Maxidex, etc. Additionally, the company's development pipeline comprises candidates like MELT-300, H-N08, CR-01, and MELT-210, being developed to address unmet needs in eye care and selected adjacent markets. Its reportable segments are: Branded, which derives maximum revenue, and ImprimisRx.
80GF Score

Get the complete analysis for HROW

Loans Receivable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$41.63
Price
$42.00
GF Value